Anti-VEGF therapies in the clinic
Publication
, Journal Article
Meadows, KL; Hurwitz, HI
Published in: Cold Spring Harbor Perspectives in Biology
November 1, 2012
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This reviewis intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies. © 2012 Cold Spring Harbor Laboratory Press; all rights reserved.
Duke Scholars
Published In
Cold Spring Harbor Perspectives in Biology
EISSN
1943-0264
Publication Date
November 1, 2012
Volume
4
Issue
11
Related Subject Headings
- 3105 Genetics
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Meadows, K. L., & Hurwitz, H. I. (2012). Anti-VEGF therapies in the clinic. Cold Spring Harbor Perspectives in Biology, 4(11).
Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.” Cold Spring Harbor Perspectives in Biology 4, no. 11 (November 1, 2012).
Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harbor Perspectives in Biology. 2012 Nov 1;4(11).
Meadows, K. L., and H. I. Hurwitz. “Anti-VEGF therapies in the clinic.” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 11, Nov. 2012.
Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harbor Perspectives in Biology. 2012 Nov 1;4(11).
Published In
Cold Spring Harbor Perspectives in Biology
EISSN
1943-0264
Publication Date
November 1, 2012
Volume
4
Issue
11
Related Subject Headings
- 3105 Genetics
- 3101 Biochemistry and cell biology